BCM
CASI

BlueCrest Capital Management’s CASI Pharmaceuticals CASI Stock Holding History

BlueCrest Capital Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,671
Closed -$111K – 1508
2018
Q1 		$111K Buy
+2,671
New +$99.7K ﹤0.01% 1348

Other funds holding CASI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BlueCrest Capital Management's CASI Position: Q2 2018 in Review

BlueCrest Capital Management sold out of CASI Pharmaceuticals (CASI) in Q2 2018, closing a stake of 2,671 shares — an estimated $111K sold.

BlueCrest Capital Management first reported a position in CASI in Q1 2018 and held it in 1 quarter. The position peaked at $111K in Q1 2018. 57 funds tracked by Wall St. Rank hold CASI as of Q2 2018.

  • BlueCrest Capital Management reported no remaining CASI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 2,671 CASI Pharmaceuticals shares in Q2 2018, an estimated $111K.
  • BlueCrest Capital Management first reported a position in CASI Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's CASI Pharmaceuticals position peaked at $111K in Q1 2018.
  • 57 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.